MANDRIXADiscuss a decisionCommercial strategy consulting · CROs · CDMOs · life-science services
Commercial strategy consulting for CROs, CDMOs and specialist life-science service companies.
Mandrixa identifies where revenue, margin and commercial opportunity are lost across pricing, positioning, pipeline, scope, delivery, partnerships and buyer decision-making. Then it changes the commercial rule that caused the loss.
Commercial strategy for specialist life-science services
Across CROs, CDMOs and life-science service companies, the visible problem is often sales. The economic constraint is usually pricing, positioning, pipeline quality, scope, buyer evidence, partnerships or capacity.
A deal-level erosion map and the commercial rules that stop the next project repeating it.
Independent evidence of what changes the decision — and what merely earns polite interest.
A defensible decision to invest, renegotiate, repair or exit each material relationship.
Capacity allocated to the work most likely to become contribution and cash — not the largest headline deal.
One executive-grade view of what is actually blocking growth — before money is spent on the wrong remedy.
A senior commercial decision layer that remains accountable until the decision changes behaviour.
Proprietary CRO and CDMO commercial strategy frameworks
Each system combines independent evidence, cross-functional challenge and a rule your executive team can continue to use.
The Mandrixa method
Name the executive decision, its owner and the evidence that would change it.
Rebuild what actually happened across commercial, finance, delivery, quality and the market.
Make the trade-off explicit, confidence-graded and owned at executive level.
Install the rule, decision artefact and review cadence that keeps it moving.
The operating standard
Founder-led commercial decision practice
Mandrixa is a commercial strategy consultancy for CROs, CDMOs and specialist life-science service companies. It is led by Alex Rickman, a life-sciences commercial leader experienced in pricing architecture, complex deals, recurring-revenue models and partnership economics.
The work sits where commercial intent collides with procurement, scientific delivery, quality, finance and executive judgement. It is not outsourced lead generation, generic marketing or RevOps.
View Alex on LinkedIn →Commercial strategy answers
Direct answers to the commercial problems that are too often treated as sales problems.
An independent commercial strategy consultant identifies why scientific capability and sales activity are not translating into sufficient revenue, margin or market share. The work typically covers positioning, pricing, pipeline quality, buyer behaviour, service architecture and commercial decision-making.
Commercial leakage is revenue or margin a company could reasonably capture but loses through weak pricing, positioning, qualification, contracting, scope control, delivery handoffs, partnerships or account management.
More business development helps only when the proposition, target market, pricing and conversion system are already sound. If qualified opportunities stall or low-quality pipeline absorbs capacity, adding sellers can amplify the wrong commercial model.
A CDMO improves margin by tracing quoted contribution through scope, technical transfer, change control, delivery and collection, then installing explicit rules for exceptions, reservations, rework and procurement concessions.
A fractional CCO is useful when the company faces material pricing, positioning, pipeline, partnership or capacity decisions but does not yet need, or cannot justify, a permanent full-time commercial executive.
Bring the decision, not a consultancy brief